RTX vs TELO · P/E 36, rev $88.60B vs $86.0M cap
RTX Corporation (RTX) versus Telomir Pharmaceuticals, Inc. Common Stock (TELO) — a side-by-side from cached financials, not a winner call.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
Telomir Pharmaceuticals, Inc. Common Stock (TELO) is a biotechnology company listed on NASDAQ.
Latest reported RTX revenue for 2025-12-31 was $88.60B. Net income was $6.73B. Revenue was up 9.7% from 2024-12-31 to 2025-12-31. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
TELO does not have a complete income-statement cache yet.
RTX currently screens at market cap $259.34B and trailing P/E 36.2. TELO currently screens at market cap $86.0M.
Not investment advice. Open the RTX and TELO stock pages for the full models.
Not investment advice.